Thyroarytenoid injection of botulinum toxin is the therapy of choice in @entity7364 . However, there is no convincing evidence as to whether unilateral or bilateral injections are to be preferred. For this reason, a prospective study was designed in which voice quality, duration of effect, and side effects were assessed. Twenty-seven @entity1 with @entity7364 were treated with percutaneous injections of botulinum toxin. The first treatment consisted of injection of 5 units in the left thyroarytenoid muscle. The second treatment, 2.5 units in both sides, took place when the effect of the first procedure had completely ceased. All @entity1 underwent both procedures. By means of self-rating scales, effects and side effects were assessed over at least 3 months. There was no difference between the procedures in duration of voice improvement, nor in the occurrence of @entity7364 . After a bilateral injection, statistically more @entity1 reported swallowing problems. However, most @entity1 preferred the bilateral injection, in spite of more and longer-lasting side effects.

Unilateral versus bilateral botulinum toxin injections in XXXX .

@entity7364 :: ('MESH:D055154', 'Disease') :: ['adductor spasmodic dysphonia', 'breathy dysphonia', 'spasmodic dysphonia'] @entity1 :: ('9606', 'Species') :: ['patients']
@entity7364 :: (MESH:D055154,Disease) :: ['adductor spasmodic dysphonia']
